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Photobiomodulation (PBM) is emerging as an effective strategy for the management of multiple inflammatory conditions,
including oral mucositis (OM) in cancer patients who receive chemotherapy or radiotherapy. Still, the poor understanding of
the mechanisms by which the light interacts with biological tissues and the heterogeneity of light sources and protocols
employed worldwide significantly limits its applicability. Reactive oxygen species (ROS) are massively generated during the early
phases of OM and play a major role in the pathogenesis of inflammation in general. Here, we report the results of a clinical and
experimental study, aimed at evaluating the effect of laser light at different wavelengths on oxidative stress in vivo in oncologic
patients suffering from OM and in vitro in two cell types abundantly present within the inflamed oral mucosa, neutrophil
polymorphonuclear (PMN) granulocytes, and keratinocytes. In addition to standard ROS detection methods, we exploited a
roGFP2-Orp1 genetically encoded sensor, allowing specific, quantitative, and dynamic imaging of redox events in living cells in
response to oxidative stress and PBM. We found that the various wavelengths differentially modulate ROS production. In
particular, the 660 nm laser light increases ROS production when applied either before or after an oxidative stimulus. In
contrast, the 970 nm laser light exerted a moderate antioxidant activity both in the saliva of OM patients and in both cell types.
The most marked reduction in the levels of ROS was detected in cells exposed either to the 800 nm laser light or to the
combination of the three wavelengths. Overall, our study demonstrates that PBM exerts different effects on the redox state of
both PMNs and keratinocytes depending on the used wavelength and prompts the validation of a multiwavelength protocol in
the clinical settings.
1. Introduction
Chemotherapy (CT) and radiant therapy (RT) are two of the
most common and widely used treatments for both solid and
haematologic tumors. While advances are constantly made
to improve their specificity towards cancer cells in order to
limit toxic effects on surrounding tissues, both therapies
often lead to debilitating side effects, such as nausea, vomit-
ing, diarrhea, and mucositis/dermatitis. Oral mucositis
(OM) is a severe inflammation of the oral and oropharyngeal
mucosa, leading to the development of extensive erythema
and ulcerations. OM importantly limits the quality of life
of patients, as it causes oral pain, dysgeusia, dysphagia, inca-
pacity of autonomous nutrition with the consequent need of
parenteral alimentation, and narcotic analgesia. In severe
cases, the anticancer therapy has to be either reduced or
stopped, with a significant negative impact on overall patient
prognosis [1, 2]. The prevalence of OM raises up to 90–
100% in patients receiving RT for head-neck cancer malig-
nancies, CT, or high-dose myeloablative chemotherapy for
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hematopoietic stem cell transplantation [3]. While the etiol-
ogy and the pathogenic mechanisms of OM have not been
fully elucidated yet, several studies have reported a major
role of DNA damage and reactive oxygen species (ROS)
during the early phases of oral and intestinal mucositis
[4–7]. Thus, either limiting ROS generation or increasing
their detoxification during CT/RT stands as a rational and
promising strategy to prevent OM onset and/or reduce its
severity [8–11].
Various approaches have been proposed to manage OM,
by either reducing its severity or preventing its onset, includ-
ing cryotherapy, growth factors, and anti-inflammatory
drugs, with very minimal efficacy [12, 13]. Laser therapy, also
known as photobiomodulation (PBM), is emerging as an
effective intervention in the management of OM [14], and
it was recently added to the guidelines issued by both the
Mucositis Study Group of the Multinational Association of
Supportive Care in Cancer and the International Society of
Oral Oncology for the prevention of OM in oncologic
patients [15]. Following these guidelines, we have success-
fully applied PBM to foster the healing of OM lesions in both
adult [16–18] and pediatric [19] patients. Yet the exact mech-
anism by which light at certain wavelengths promotes muco-
sal healing, also reducing pain and inflammation, is not
clearly understood [20, 21].
PBM is based on the assumption that red (600–700nm)
and near-infrared (NIR, 770–1200 nm) light at low irradi-
ance excites specific chromophores, such as the cytochrome
c oxidase, essentially located inside the mitochondria, which
represents the main source for intracellular ROS generation.
In vitro studies have so far provided conflicting results on the
effect of PBM on ROS balance. While PBM induces a modest
and dose-dependent increase in ROS production in normal
cell lines, it appears to reduce ROS levels in cells previously
exposed to oxidative stress [22, 23]. Whether these effects
of PBM can be reproduced on various cell types and to what
extent the various wavelengths are differentially able to mod-
ulate ROS production still remain open questions.
Here, we report the results of a clinical and experimental
study, aimed at evaluating the effect of PBM on oxidative
stress in vivo in oncologic patients suffering from CT/RT-
induced OM and in vitro in keratinocytes and neutrophil
polymorphonuclear (PMN) granulocytes. In addition, we
exploited the roGFP2-Orp1 sensor to monitor redox changes
in response to oxidative stress and laser light at different
wavelengths in immortalized human keratinocytes.
2. Materials and Methods
2.1. Laser Device. A gallium arsenide (GaAs) + indium gal-
lium aluminum arsenide phosphide (InGaAlAsP) diode
laser device (class IV, K-Laser Cube series, K-Laser d.o.o.,
Sežana, Slovenia) was used to perform all the experiments.
The laser device is associated with a programmable scanner
conveniently designed to provide uniform irradiation to dif-
ferent multiwell plates (12, 24, and 96-well plates). Plate
covers were removed during irradiation, and the emission
tip was held perpendicular above the cells. The emitted light
completely covered the irradiated field of each culture plate,
and power was adapted to the spot size to provide the
desired irradiance and fluence using an optical power meter
(LaserPoint Plus+, Via Burona, 51-20090 Vimodrone, Milan,
Italy). The device is able to provide 660nm, 800nm, and
970 nm wavelength laser light in different combinations of
power and energy.
2.2. Clinical Study. The study was performed according to the
ethical standards of the 1975 Declaration of Helsinki (7th
revision, 2013) upon approval by the local ethical committee.
All subjects enrolled in the study signed an informed consent
to participate. A total of 10 patients affected by OM were
enrolled at the Oral Medicine and Pathology Department,
Ospedale Maggiore, Trieste, Italy according to the following
inclusion criteria:
(a) Age between 40 and 95 years
(b) Diagnosis of a solid or haematologic malignancy
undergoing CT and/or RT
(c) Presence of OM of grade 2 or 3 (CTC) related to
ongoing oncological therapies
(d) Availability to undergo PBM for four consecutive
days (T0, T1, T2, T3, and one follow-up recall,
CTRL)
The exclusion criteria are the following:
(a) OM previously treated by PBM
(b) Application of topical oral medication
(c) Systemic antioxidant therapy
A schematic representation of the study design is shown
in Figure 1(a). During the first visit on day 0 (T0), experi-
enced clinicians registered information about patients’ clini-
cal history and scored OM severity according to the common
toxicity criteria (CTC) scale (WHO, 1976), considering
ulceration and erythema distribution and size. A 0–10 visual
analogue scale (VAS) was employed to quantify subjective
parameters, including pain, difficulties in swallowing, speak-
ing, and chewing. The patients were treated with PBM at
T0, T1, T2, and T3 using a previously optimized protocol
(λ 970nm, 200mW/cm2, 6 J/cm2, in continuouswave) [18, 24].
Both patients and operators wore protective glasses during
the treatment to avoid possible eye damage. PBM was pro-
vided using a rotatory motion all over the oral cavity to cover
both ulcerated and healthy areas, keeping a 3 cm distance
between the laser probe and the tissue. Irradiation time was
calculated considering a mean oral mucosa surface area of
215 cm2 [25].
Unstimulated saliva samples were collected for 5 minutes
before and after each PBM session (T0–T4) and once on day
5 (CTRL). Patients were asked to fast for at least 2 hours
before sampling, avoiding tooth brushing, excess alcohol
intake, and physical activity since the previous evening.
Patients rinsed the mouth with water for 1 minute and then
spit saliva for 5 minutes in a sterile collection tube. Samples
were stored at −20°C until analysis.
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2.3. TOS Assay.Oxidative stress status was measured in saliva
at each time point using the total oxidant status (TOS)
method [26]. This method is based on the principle that oxi-
dant species present in the saliva oxidize the ferrous ion-o-
dianisidine complex to ferric ion, creating a coloured com-
plex with xylenol orange in an acidic medium. In each well
of a 96 multiwell plate, centrifuged saliva (35μL) was added
to 225μL of reagent 1 (xylenol orange 150μM, NaCl
140mM, and glycerol 1.35M in 25mM H2SO4 solution,
pH1.75). Subsequently, 11μL of reagent 2 (ferrous ion
5mM and o-dianisidine 10mM in 25mM H2SO4 solution)
was added. The solutions were gently mixed for 5 minutes,
and then the absorbance was measured with a multiwell
reader spectrophotometer (Glomax multi+ detection system,
Promega, Italy) at OD560. The absorbance measured before
mixing reagent 1 and reagent 2 was used as a sample blank.
The assay was calibrated using standard aqueous solutions
of hydrogen peroxide (H2O2). TOS values are reported as
the mean of 4 measurements± standard deviation and are
expressed as micromolar hydrogen peroxide equivalent per
liter (μmol H2O2 Equiv/L).
2.4. Cells.Human keratinocytes (HaCaT) were maintained in
DMEM culture medium supplemented with 10% fetal bovine
serum, 100U/mL penicillin/streptomycin, and 2mM gluta-
mine (Euroclone, Pero, Milan, Italy). Cells were seeded one
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Figure 1: Effect of PBM on clinical parameters and oxidative stress in OM patients. (a) Schematic representation of the study design. Enrolled
patients were treated with PBM for 4 consecutive days followed by a control session on day 5. Saliva samples were collected on treatment days
before and after each PBM session and once on day 5. (b) Evaluation of OM severity by VAS score (left panel) and CTC score (right panel)
over time. Both parameters significantly decreased over time (Friedman’s test p = 0 0003 for VAS and p = 0 0034 for CTC). ∗∗Dunn’s multiple
comparison test p < 0 001 compared to T0. (c) Percentage of patients indicating the presence (black bars) or absence (white bars) of either
pain or functional alterations in swallowing, chewing, or speaking over time. (d) TOS levels in the patient saliva at the indicated time
points. Data are the means± SD. ∗Mann–Whitney U test p < 0 05.
3Oxidative Medicine and Cellular Longevity
day prior to the experiment (10,000 cells/well in 96 multiwell
plates and 50,000 cells/well in 24 multiwell plates), avoiding
the use of cells over the 10th passage.
2.5. Evaluation of Intracellular ROS Production and Kinetics
in PMN. PMN isolation from the venous whole blood of 5
healthy volunteers was performed using a Ficoll gradient
(Ficoll-Paque Plus, GE Healthcare) through a centrifugation
of 400×g for 30 minutes. Erythrocytes were lysed with a
buffered ammonium chloride solution (ammonium [Tris
(1.7mM)-NH4Cl (16mM)]). The PMNs were washed in
HANKS balanced salt solution (150×g for 10 minutes)
and seeded at a concentration of 106 cells/mL in RPMI-
1640 medium (Sigma-Aldrich) in 96-well plates (100 μL
in each well).
After isolation, PMNs were either stimulated with
100ng/mL LPS (lipopolysaccharide from Escherichia coli
055:B5) for 15 minutes or not and then exposed to laser light
at either 970nm (λ 970nm, irradiance 200mW/cm2, fluence
6 J/cm2) or 660nm (λ 660nm, irradiance 50mW/cm2, flu-
ence 3 J/cm2). The cells were then incubated for 10′ with 2′
7′dichlorofluorescein diacetate (DCFH-DA, Sigma-Aldrich,
Saint Louis, Missouri, USA), and OD529 emission was mea-
sured using a spectrophotometer (Envision plate reader,
PerkinElmer, Waltham, Massachusetts, USA) for 2 hours
(1 read/minute). ROS levels are reported as the mean of 4
measurements± standard deviation.
2.6. Real-Time Quantification of Oxidative Stress Using
Fluorescent Protein-Based Redox Probes in Keratinocytes.
HaCaT cells were seeded three days before the experiment
in 8-well Ibidi μ-slides (100,000 cells/well). The following
day, cells were transfected using lipofectamine 2000 with a
plasmid expressing roGFP2-Orp1 [27]. After 48 hours, the
cells were treated with different PBM protocols [24] and
imaged at a Leica LSM 810 confocal microscope.
The following laser protocols were applied, either individ-
ually or in combination: (i) λ 660nm, irradiance 50mW/cm2,
fluence 3 J/cm2, continuous wave; (ii) λ 800nm, irradiance
200mW/cm2, fluence 6 J/cm2, continuous wave; and (iii) λ
970nm, irradiance 200mW/cm2, fluence 6 J/cm2, continu-
ous wave. An oxidative stimulus (0.5mM H2O2) was added
either 10 seconds prior to the laser light or immediately after
the laser light. Cells were imaged for 240 seconds (12 frames
every 20 seconds). The ratio between the fluorescence
excited at 408nm and 488 nm was used as a surrogate indi-
cator of the redox status of the cells, with an expected
increase in the 408/488 nm ratio in the presence of oxidative
stress. Images were analyzed using the ImageJ software. ROS
levels are reported as the mean of 4 measurements± stan-
dard deviation.
2.7. Keratinocyte Viability and Oxidative Stress Assay
following 5-FU. 5-FU 0.1mg/mL (F6627, Sigma-Aldrich,
Saint Louis, Missouri, USA) was added to HaCaT cells for
18 hours, followed by PBM using combined laser wave-
lengths (λ 660nm, irradiance 50mW/cm2, fluence 3 J/cm2;
λ 800nm, irradiance 200mW/cm2, fluence 6 J/cm2; and λ
970nm, irradiance 200mW/cm2, fluence 6 J/cm2). After
additional 24 hours, the MTT assay was performed following
the manufacturer’s instructions (Trevigen, Gaithersburg,
Maryland, USA). Results are expressed as % OD570 absor-
bance relative to untreated cells. ROS production was mea-
sured 30 minutes after PBM using the cell-permeant 2′,7′
-dichlorodihydrofluorescein diacetate (H2DCFDA) dye
(D399, Invitrogen, Thermo Fisher Scientific, Waltham,
Massachusetts, USA), and the obtained fluorescence was
normalized on living cells. The results are reported as the
mean of 8 measurements± standard deviation.
2.8. Gene Expression Analysis. Total RNA was extracted 30
minutes after PBM using Eurogold Trifast reagent
(EMR507100, Euroclone, Pero, Milan, Italy) following the
manufacturer’s instructions and retrotranscribed using the
High-Capacity cDNA Reverse transcription kit (Thermo
Fisher Scientific, Waltham, Massachusetts, USA). Taq-
manTM probes for HMOX1 (hs00167309_m1) and SOD2
(hs01110250_m1) genes and β-actin (as calibrator and refer-
ence, ACTB: Hs99999903_m1) were used to quantify the rel-
ative mRNAs using an Applied Biosystems 7900HT Fast
Real-Time PCR System (Thermo Fisher Scientific, Waltham,
Massachusetts, USA) platform. Data were analyzed using the
Relative Quantification manager software (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) using untreated
cells as reference. The experiment was performed in three
replicates including duplicate wells, and the results are
expressed as the mean± standard deviation.
2.9. Statistical Analysis. The Prism 6.0 software (GraphPad
Software, La Jolla, California, USA) was used to perform sta-
tistical analysis. All statistical assessments were two-sided,
and a p value < 0.05 was used for the rejection of the null
hypothesis. Friedman’s test was employed to test the signif-
icance of changes over time in VAS and CTC scores, while
Dunn’s multiple comparison test was used as post hoc to
compare each pair of time points. Pearson’s nonparametric
correlation test was used to evaluate the relation between
TOS levels and VAS or CTC scores at each time point.
The Mann–Whitney U test was employed to evaluate differ-
ences between treated and untreated samples. The Mann–
Whitney U test was performed to determine gene expression
differences among samples. Linear regression analysis was
employed to evaluate differences in PMN ROS levels among
groups and over time. Two-way ANOVA was applied to
determine the significance of differences between the curves
representing oxidative status in keratinocytes with geneti-
cally encoded redox probes treated with H2O2 with and
without PBM.
3. Results
3.1. PBM Improves Clinical Parameters in OM Patients and
Determines a Transient Reduction in the Oxidant Status of
the Saliva. Baseline demographic and clinical characteristics
of the 10 patients suffering from OM who completed the
study are reported in Table 1. PBM was performed daily for
4 consecutive days (T0 to T3, Figure 1(a)) and well tolerated
by all patients, without any adverse event. Effectiveness of
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PBM was confirmed by the progressive decrease of both
the VAS and the CTC scores over time, as reported in
Figure 1(b) (Friedman’s test p = 0 0003 for VAS and p =
0 0034 for CTC). The number of patients reporting dis-
comfort in subjective parameters (swallowing, chewing
and speaking) also decreased over time following PBM
(Figure 1(c)).
In the same patients, we analyzed the total oxidant status
(TOS) in the saliva before and after each PBM session, as well
as the day following the last session (CTRL). TOS level was
significantly correlated to the VAS score at T3 and T4 (Pear-
son’s nonparametric correlation test p < 0 05), but not to the
CTC score. While the oxidative stress did not change after
PBM at T0, starting from T1, ROS levels decreased promptly
after each PBM session (Mann–Whitney U test p < 0 01 for
T1, T2, and T3). Despite this constant trend, ROS levels
increased again during the following 24 hours, as well as at
day 5 (CTRL). Thus, PBM transiently reduces oxidative
stress after treatment, but this effect lasts less than 24 hours.
3.2. PBM at Different Wavelengths Modulate ROS Production
in Both Stimulated and Unstimulated PMNs. As PMNs are
known to be a major source of ROS in inflammatory condi-
tions, including OM, we investigated the potential of PBM,
set at two different wavelengths commonly employed in the
clinics (970 nm and 660nm), to modulate ROS production
in unstimulated and LPS-stimulated PMNs. In unstimulated
PMNs (Figure 2(a)), the two wavelengths had opposite
effects. While the 970 nm protocol significantly reduced
ROS levels (linear regression p = 0 023 and p < 0 0001 after
90 and 120 minutes, respectively), the 660nm protocol
increased ROS levels at 2 hours after PBM (linear regression
p < 0 0001). As expected, stimulation of PMNs with LPS
resulted in increased ROS production in all experimental
groups (Figure 2(b)). In line with the results obtained with
unstimulated PMNs, we observed a reduction in ROS levels
upon irradiation with the 970nm protocol, whereas the
660nm did not exert any effect.
3.3. Dynamic Real-Time Detection of PBM-Induced Redox
Changes in Keratinocytes Using Genetically Encoded
Fluorescent Sensors. Compared to standard ROS detection
methods, based on the use of chemical indicators, genetically
encoded probes, exploiting redox-sensitive fluorescent pro-
teins, allow specific, quantitative, and dynamic imaging of
redox events in living cells [27]. To monitor redox changes
in keratinocytes upon PBM, we employed a genetically
encoded probe based on the redox-active green fluorescent
protein 2 (roGFP2) fused to Orp1, a highly sensitive thiol
peroxidase that is oxidized by H2O2 [28]. By introducing
the roGFP2-Orp1 probe in keratinocytes, we could monitor
any change in the intracellular redox state upon exposure
to PBM either in the absence or in the presence of H2O2-
induced oxidative stress. This time we compared the effect
of the three wavelengths (660 nm, 800nm, and 970nm) that
have been so far considered for the treatment of OM and
other inflammatory conditions.
First, we determined whether PBM induces any change
in the redox state of cells at baseline and found that any of
the three tested laser protocols, and not even their combina-
tion, exert a significant effect (Figures 3(a)–3(d)). As
expected, the addition of H2O2 determined a rapid increase
in ROS levels (Figure 3(e)). Whereas the 660nm protocol
did not induce any change in ROS production (p = ns), the
970 nm protocol and, even more evident, the 800 nm proto-
col significantly reduced ROS levels (p < 0 01 and 0.001,
respectively; Figures 3(a)–3(c)). Of notice, the simultaneous
delivery of the three wavelengths was also very effective in
reducing the oxidative status upon exposure to H2O2
(p < 0 01; Figure 3(d)). We also tested whether PBM was
able to modulate ROS levels when applied to cells previously
exposed to H2O2. In agreement with the results obtained in
PMNs, the 660nm protocol further increased ROS levels
(p < 0 01; Figure 3(f)). In contrast, both the 800nm and
the combined protocols significantly reduced ROS produc-
tion also in this condition (p < 0 01 and p < 0 05, respec-
tively; Figures 3(g)–3(i)).
3.4. PBM Improves Keratinocyte Resistance to Oxidative
Stress Induced by 5-Fluorouracil In Vitro. Based on the prom-
ising results obtained using the multiwavelength PBM proto-
col, we wanted to confirm its actual capacity to reduce
oxidative stress in keratinocytes treated with 5-fluorouracil
(5-FU) treatment, partially mimicking the scenario of OM
patients. Indeed, 5-FU is widely used in patients affected by
different solid tumors, including five patients enrolled in
Table 1: Selected baseline characteristics of the patients enrolled in the study.
Patient Age Gender Malignancy Anticancer therapy VAS score at T0 CTC score at T0
1 58 M Gastrointestinal CT 2 2
2 58 F Breast CT 2 2
3 62 M Head neck CT and RT 8 2
4 92 F Head neck RT 8 2
5 74 M Haematological CT 7 3
6 56 M Head neck CT 5 2
7 65 M Gastrointestinal CT 6 3
8 44 M Haematological CT 2 2
9 69 M Head neck CT and RT 4 2
10 71 M Head neck RT 8 3
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our study. 5-FU acts as an inducing cell apoptosis through
several mechanisms, including the generation of mitochon-
drial oxidative stress [29]. We treated human keratinocytes
with 5-FU for 18 hours and found a significant rate of cell
death compared to untreated cells (Mann–Whitney U test p
< 0 001), as represented in Figure 4(a). When the same cells
were exposed to PBM after 5-FU treatment, cell viability was
significantly higher (Mann–Whitney U test p < 0 001).
Besides cell death, 5-FU also induced ROS production in
human keratinocytes (Mann–Whitney U test p = 0 02), as
assessed using the H2DCFDA dye, while PBM significantly
lowered the level of intracellular ROS in both 5-FU treated
and untreated cells (Mann–Whitney U test p = 0 048 and
p = 0 015, respectively; Figure 4(b)).
We also assessed the expression levels of HMOX1 and
SOD2, two enzymes playing a key role in the cellular
response to oxidative stress, and consistently found that 5-
FU upregulated both enzymes as expected, whereas PBM
markedly decreased their expression (Mann–Whitney U
test p = 0 03 for both genes), as shown in Figures 4(c) and
4(d). Similar to what was observed for ROS production,
exposure of the cells to PBM resulted in a significant down-
regulation of HMOX1 and SOD2, even in cells treated with
5-FU (Mann–Whitney U test p = 0 03 for both genes,
Figures 4(c) and 4(d)).
4. Discussion
Despite increasing evidence of its effectiveness in the treat-
ment of OM and other inflammatory conditions, PBM still
does not stand as a universally recognized and accepted
therapy, essentially because of the variety of light sources
and irradiation protocols employed in different trials in
terms of wavelength (usually in the range of 600–
1100 nm), irradiance, and fluence. Therefore, a major effort
is needed to understand whether the different wavelengths
exert specific biological effects and to establish the optimal
parameters to be used to achieve the best therapeutic activity
in each condition.
This work contributes to establishing the capacity of
laser light to modulate oxidative stress, which is crucial in
OM onset and progression. We report our clinical experi-
ence on cancer patients suffering from OM induced by either
CT or RT. These patients were treated with a protocol opti-
mized on the base of our previous clinical and experimental
work [18, 24], using 970nm laser light. Consistent with
previous studies, this treatment was effective in improving
all clinical parameters, starting from the fifth day of PBM.
We then moved to assess the levels of ROS in the saliva of
the same patients and observed a marked antioxidant
activity exerted by each PBM session. However, this drop
in ROS level was transient and not maintained during
the 24 hours of posttreatment.
To better understand the cellular mechanism and the
dynamics underlying this effect, with the ultimate goal of
optimizing our clinical protocol, we wanted to assess the
effect of multiple wavelengths of laser light on two different
cell types, reasonably representing the major sources of
ROS in OM, PMNs, and keratinocytes.
First, we evaluated the effect of red (660 nm) and near-
infrared (970 nm) laser light on PMNs, either in resting
conditions or upon stimulation with LPS and observed an
opposite response. While the 970nm light reduced ROS pro-
duction in both conditions, the 660nm light increased ROS
levels in unstimulated PMNs and did not exert any effect in
LPS-stimulated cells. Our result is also in accordance with
the work by Cerdeira et al. [30], in which neutrophil irradia-
tion with 660 nm laser light resulted in a significant increase
in their respiratory burst, associated with intra- and extracel-
lular superoxide radical production and improved fungicidal
activity against Candida albicans. Our data add an important
piece of evidence, showing that different wavelengths exert
specific and even opposite effects on ROS production. While
a definitive explanation for these differences is still missing, it
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Figure 2: Effect of PBM on intracellular ROS production in unstimulated PMNs and in PMNs stimulated with LPS. (a) Monitoring of
fluorescence detection units at OD529 over time in unstimulated PMNs. NT: not treated, 970: treated with 970 nm laser light, and 660:
treated with 660 nm laser light. ∗Linear regression analysis p < 0 05 compared to NT. ∗∗∗Linear regression analysis p < 0 0001 compared to
NT. (b) Monitoring of fluorescence detection units at OD529 over time in PMNs stimulated with LPS. NT: not treated, 970: treated with
970 nm laser light, and 660: treated with 660 nm laser light. ∗∗∗Linear regression analysis p < 0 0001 compared to NT.
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Figure 3: Continued.
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Figure 3: Real-time evaluation of the effect of PBM on the redox status in HaCaT cells using genetically encoded fluorescent sensors. (a–d)
Cells were treated with PBM at the indicated wavelength (660 nm in (a), 800 nm in (b), and 970 nm in (c) and the combination of the three
wavelengths in (d)) and subsequently exposed to 0.5mMH2O2. Measurement of fluorescence started immediately after exposure to oxidative
stress. Data are the means± SD. Signals recorded in treated cells and in cells treated only with PBM are also plotted. (e) Representative images
of the fluorescence intensity at 405 nm (left) and 488 nm (center) and transmitted light (right) of the same cells at baseline (upper raw) and
upon treatment with 0.5mM H2O2 (lower raw). (f–i) Cells were first treated with 0.5mM H2O2 and subsequently exposed to PBM at the
indicated wavelength (660 nm in (a), 800 nm in (b), and 970 nm in (c) and the combination of the three wavelengths in (d)).
Measurement of fluorescence started 20 seconds prior to the exposure to oxidative stress. Data are the means± SD.
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Figure 4: Effect of PBM on keratinocyte survival and oxidative stress induced by exposure to 5-FU (0.1mg/ml). (a) MTT assay showing the
percentage of living cells in the absence of any treatment (not treated, NT) and after exposure to either PBM, 5-FU, or their combination.
(b) ROS production (normalized to the percentage of living cells) in the absence of any treatment (not treated, NT) and after exposure to
either PBM, 5-FU, or their combination. (c) Levels of HMOX1 gene expression in the absence of any treatment (not treated, NT) and after
exposure to either PBM, 5-FU, or their combination. (d) Levels of SOD2 gene expression in the absence of any treatment (not treated, NT)
and after exposure to either PBM, 5-FU, or their combination. ∗Mann–Whitney U test p < 0 05; ∗∗Mann–Whitney U test p < 0 01. Data are
the means± SD.
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might depend on the fact that intracellular chromophores,
and in particular the cytochrome c oxidase, which is consid-
ered the main target of PBM, change their absorption spectra
depending on their oxidation state [31].
This implies that PBM cannot be considered a single
therapeutic entity and that the optimal wavelength can be
chosen not only on the base of the depth of tissue penetration
but also considering the biological activity exerted on the
irradiated cells. This is particularly relevant considering that
neutrophils of patients undergoing CT usually present a
defective capacity in ROS generation, with reduced produc-
tion of IL-1β and overall impaired antimicrobial function
[32–34]. Thus, the use of a laser wavelength able to stimulate
ROS production in PMNs may represent a powerful tool to
boost their ability to respond to infections in immunocom-
promised patients.
To understand whether the same effects are also exerted
on keratinocytes, we exploited genetically encoded redox
biosensors to monitor ROS production in real time in
response to PBM, this time also testing an additional wave-
length (800 nm), which is being progressively used to reach
inflamed tissues in depth, as this wavelength is poorly
absorbed by water. We confirmed that the 660nm laser light
increases ROS production when applied either before or
after an oxidative stimulus. More importantly, we found that
the 970nm laser light exerted a moderate antioxidant activ-
ity, whereas a striking reduction in the levels of ROS was
detected in cells exposed to either the 800nm laser light or
the combination of the three different wavelengths.
Since this multiwavelength PBM protocol could repre-
sent a promising therapeutic tool to be introduced into the
clinics, we wanted to confirm its actual capacity to reduce
oxidative stress in keratinocytes treated with 5-FU treatment,
partially mimicking the scenario of OM patients. We found
that this combined PBM protocol reduced ROS levels and
ROS-induced genes in both untreated and 5-FU-treated cells.
These results differ partially from those obtained using
single wavelengths, in which PBM seems to decrease ROS
levels in stressed or injured tissues, while increasing them
in healthy ones [35]. For instance, Tatmatsu-Rocha et al.
showed that the 904nm laser light reduces oxidative stress
markers in the wounded skin of diabetic mice, whereas it
increased them in irradiated controls [36]. In primary corti-
cal neurons, PBM at 810nm increased ROS levels in basal
conditions, but it reduced ROS when the neurons were
treated with oxidant reagents [23]. The same wavelength
was reported to lead to ROS increment in healthy murine
embryonic fibroblast through the activation of nuclear factor
kappa B (NF-κB) [37]. Additional variability could depend
on the timing at which ROS levels are assessed following
PBM. While in healthy cells our combined PBM protocol
did not induce any significant change in ROS levels during
the first 5 minutes, as assessed using the fluorescent sensors,
it was effective in reducing both ROS generation and ROS-
induced gene expression after 18 hours, as determined by
the H2DCFDA assay and real-time PCR.
These findings suggest that a combined multiwavelength
irradiation protocol may be considered, to reach tissues
located at different depths and exploit the different
characteristics of single wavelengths, i.e., increasing ROS
levels in neutrophils by the 660nm laser light and reducing
the oxidative stress in keratinocytes by the 800 and 970nm
light. Future studies using both cellular and animal models
will further confirm the rationale and efficacy of this
approach.
5. Conclusions
Overall, our study demonstrates that PBM exerts different
effects on the redox state of both PMNs and keratinocytes,
depending on the wavelength, and prompts the validation
of a multiwavelength protocol in the clinical settings.
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